دورية أكاديمية
Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population.
| العنوان: | Clinical and Economic Impact of Adopting Noninvasive Prenatal Testing as a Primary Screening Method for Fetal Aneuploidies in the General Pregnancy Population. |
|---|---|
| المؤلفون: | Kostenko, Emilia, Chantraine, Frédéric, Vandeweyer, Katleen, Schmid, Maximilian, Lefevre, Alex, Hertz, Deanna, Zelle, Laura, Bartha, Jose Luis, Di Renzo, Gian Carlo |
| المصدر: | Fetal Diagnosis and Therapy, 45 (6), 413 - 423 (2019) |
| بيانات النشر: | S. Karger AG, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Cell-free DNA, Cost effectiveness, Down syndrome, Economic evaluation, Fetal diagnosis, Genetic testing, Maternal serum screening, Noninvasive prenatal diagnosis, Prenatal screening, Trisomy, Cost-Benefit Analysis, Decision Support Techniques, Female, Humans, Pregnancy, Uncertainty, Aneuploidy, Genetic Testing, Noninvasive Prenatal Testing, Pediatrics, Perinatology and Child Health, Embryology, Radiology, Nuclear Medicine and Imaging, Obstetrics and Gynecology, General Medicine, Human health sciences, Reproductive medicine (gynecology, andrology, obstetrics), Sciences de la santé humaine, Médecine de la reproduction (Gynécologie, andrologie, obstétrique) |
| الوصف: | [en] OBJECTIVE: To evaluate the clinical and economic impact of adopting noninvasive prenatal testing (NIPT) using circulating cell-free DNA as a first-line screening method for trisomy 21, 18, and 13 in the general pregnancy population.METHODS: A decision-analytical model was developed to assess the impact of adopting NIPT as a primary screening test compared to conventional screening methods. The model takes the Belgium perspective and includes only the direct medical cost of screening, diagnosis, and procedure-related complications. NIPT costs are EUR 260. Clinical outcomes and the cost per trisomy detected were assessed. Sensitivity analysis measured the impact of NIPT false-positive rate (FPR) on modelled results.RESULTS: The cost per trisomy detected was EUR 63,016 for conventional screening versus EUR 66,633 for NIPT, with a difference of EUR 3,617. NIPT reduced unnecessary invasive tests by 94.8%, decreased procedure-related miscarriages by 90.8%, and increased trisomies detected by 29.1%. Increasing the FPR of NIPT (from < 0.01 to 1.0%) increased the average number of invasive procedures required to diagnose a trisomy from 2.2 to 4.5, respectively.CONCLUSION: NIPT first-line screening at a reasonable cost is cost-effective and provides better clinical outcomes. However, modelled results are dependent on the adoption of an NIPT with a low FPR. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article peer reviewed |
| اللغة: | English |
| العلاقة: | https://www.karger.com/Article/Pdf/491750Test; urn:issn:1015-3837; urn:issn:1421-9964 |
| DOI: | 10.1159/000491750 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/312138Test |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2Test info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.312138 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1159/000491750 |
|---|